Projects per year
Personal profile
Biography
Dr Michael Fahey
School of Clinical Sciences at Monash Health
Monash Medical Centre
Telephone: +61 3 9594 3499
Email: [email protected]
Areas of expertise
- Commentary: Paediatric neurology; Neurogenetics.
- Supervision: Neurology; Neurogenetics; Cerebral palsy.
Neurogenetics
In Australia, a child is born with Cerebral Palsy every 18 hours. As a physician and the Head of Paediatric Neurology at Monash Medical Centre, Dr Michael Fahey is too familiar with the human face of the condition. However, as a researcher specialising in neurogenetics, Michael also knows there is work underway that could one day lead to a cure.
Neurogenetics is concerned with the link between our genes and the diseases and disorders of the nervous system. Michael's research focuses on using neurogenetics to understand the causes of movement disorders and diseases of the muscle and nerve. These include Cerebral Palsy, a disease that affects thousands of Australians.
While scientific researchers of Michael's standing - he has undertaken research and training with Monash University, Melbourne University, the Royal Australasian College of Physicians, the Alfred Hospital, Sydney Children's Hospital and the Murdoch Children's Research Institute - are cautious about raising expectations about the possibility of finding a cure for disorders such as Cerebral Palsy, he is excited by the insights genetic research is generating.
"The next stage of research into these conditions is going to be to try and evolve treatments for them," Michael says.
"At the moment these are conditions which we are becoming increasingly good at diagnosing and a genetic diagnosis will allow us to understand the mechanisms behind the disease. Our hope is that for many of the conditions that we're looking at treatments that will be developed within my working lifespan.
"this is about moving beyond managing the disease to actively look for cures. That's our motivation, and I hope this is real. This kind of research works on long timescales, I think that's fair to say, but it's always hoped that treatments will evolve quickly from the discover of the causes behind the condition."
Michael believes that Monash and its network of partners are in a great position to be world leaders in the field. He is currently collaborating on research into treatments for Cerebral Palsy with researchers at the Ritchie Centre, part of the Monash Institute of Medical Research. The work has evolved out of Ritchie Centre strengths in women's health and foetal and newborn medicine. It focuses on melatonin, a hormone produced in the brain, and Michael is confident the research will soon move to human trials.
In addition to working with the Ritchie Centre, Michael also collaborates on gene discovery research with Genetic Health Services Victoria and experts at the Alfred Hospital. He is also involved in the treatment of rare neuro-metabolic diseases with partners at the Royal Melbourne Hospital.
Outside of the lab, Michael maintains a heavy workload as a physician. He is Head of the Paediatric Neurology Unit at Monash Medical Centre, and works in neurogenetics clinics at the Royal Melbourne and St Vincents Hospitals. He is also collaborating with Professor Elsdon Storey, Head of the Neurology and Stroke Unit at the Alfred. He still finds the time to act as neurologist at the Paediatric Rehabilitation Clinic and has co-founded a mitochondrial clinic.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Collaborations and top research areas from the last five years
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy.
Fahey, M. (Primary Chief Investigator (PCI))
30/08/23 → 29/08/28
Project: Research
-
Investigating the effects of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on gene regulation and immune dysfunction in paediatric acute-onset neuropsychiatric syndrome: An open-label study
Fahey, M. (Primary Chief Investigator (PCI))
25/07/23 → 24/07/28
Project: Research
-
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks
Fahey, M. (Primary Chief Investigator (PCI))
25/07/23 → 24/07/28
Project: Research
-
MitoHOPE: Introducing Mitochondrial Donation in AustraliaL The MitoHOPE (Healthy Outcomes Pilot and Evaluation) Program
Carroll, J. (Primary Chief Investigator (PCI)), Herbert, M. (Chief Investigator (CI)), Christodoulou, J. (Chief Investigator (CI)), Thorburn, D. R. (Chief Investigator (CI)), Mills, C. (Chief Investigator (CI)), Zander-Fox, D. L. (Chief Investigator (CI)), Robker, R. (Chief Investigator (CI)), Rombauts, L. (Chief Investigator (CI)), Sallevelt, S. (Chief Investigator (CI)), Ludlow, K. (Chief Investigator (CI)), Coman, D. J. (Chief Investigator (CI)), Ellaway, C. (Chief Investigator (CI)), Mackey, D. A. (Chief Investigator (CI)), Delatycki, M. B. (Chief Investigator (CI)), Yau, W. Y. (Chief Investigator (CI)), Tchan, M. C. (Chief Investigator (CI)), Long, J. C. (Chief Investigator (CI)), Hardy, T. (Chief Investigator (CI)), Adhikari, D. (Chief Investigator (CI)), Choudhary, M. (Chief Investigator (CI)), Hyslop, L. A. (Chief Investigator (CI)), Mann, J. (Chief Investigator (CI)), Ryan, M. (Chief Investigator (CI)), Hodges, R. (Chief Investigator (CI)), Hui, L. (Chief Investigator (CI)), Kamien, B. A. (Chief Investigator (CI)), Mallett, A. J. (Chief Investigator (CI)), Wallis, M. J. (Chief Investigator (CI)), Wall, M. (Chief Investigator (CI)), Zoungas, S. (Chief Investigator (CI)), Goranitis, I. (Chief Investigator (CI)), Gyngell, C. (Chief Investigator (CI)), Hammarberg, K. (Chief Investigator (CI)), Sparrow, R. (Chief Investigator (CI)), Warren, N. (Chief Investigator (CI)), Fahey, M. (Chief Investigator (CI)), Stutterd, C. A. (Associate Investigator (AI)), Schweitzer, D. R. (Associate Investigator (AI)), McGillivray, G. (Associate Investigator (AI)), Savulescu, J. (Associate Investigator (AI)), Panetta, J. (Associate Investigator (AI)), Kava, M. P. (Associate Investigator (AI)), Freckmann, M.-L. (Associate Investigator (AI)), Lynch, M. (Associate Investigator (AI)), Lamont, P. J. (Associate Investigator (AI)), Scott, R. (Associate Investigator (AI)), Ware, T. (Associate Investigator (AI)), Mowat, D. (Associate Investigator (AI)), Jones, K. J. (Associate Investigator (AI)), Green, S. (Associate Investigator (AI)), Wolfe, R. (Associate Investigator (AI)), Hackett, A. (Associate Investigator (AI)), Bratkovic, D. (Associate Investigator (AI)), Horton, A. (Associate Investigator (AI)) & Blok, R. (Project Manager)
Monash University – Internal Faculty Contribution, Australian Genomics, James Cook University, Lyons Eye Institute Limited, Macquarie University, Murdoch Children's Research Institute, Australian Mitochondrial Disease Foundation Limited (trading as Mito Foundation), Monash IVF Group Limited, Perron Institute for Neurological and Translational Science Limited, Queensland Children's Hosptial , Tasmanian Clinical Genetics Service, University of Adelaide, Victorian Assisted Reproductive Treatment Authority (VARTA) (Victoria), Women's and Children's Health Care Network Incorporated, Western Sydney Local Health District (WSLHD)
1/06/23 → 31/05/29
Project: Research
-
A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies
Fahey, M. (Primary Chief Investigator (PCI))
29/03/23 → 28/03/28
Project: Research
-
A description and a diagnostic framework: Synergy for practical cerebral palsy diagnosis and care
Aravamuthan, B., Fehlings, D., Novak, I., Fahey, M., Fowler, E., Kruer, M. & Chambers, H., 2025, (Accepted/In press) In: Developmental Medicine and Child Neurology. 2 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Brain MRI before and at term equivalent age predicts motor and cognitive outcomes in very preterm infants
Pagnozzi, A. M., Pannek, K., Boyd, R. N., van Eijk, L., George, J. M., Bora, S., Bradford, D. K., Fahey, M., Ditchfield, M., Malhotra, A., Colditz, P. B. & Fripp, J., Jun 2025, In: Neuroimage: Reports. 5, 2, 12 p., 100262.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
Investigating the impact of severe maternal SARS-CoV-2 infection on infant DNA methylation and neurodevelopment
Hill, R. A., Gibbons, A., Suwakulsiri, W., Taseska, A., Darke, H., Malhotra, A., Yee, H., Fahey, M., Hunt, R. W., Lim, I., Palmer, K. & Sundram, S., May 2025, In: Molecular Psychiatry. 30, 5, p. 1976-1984 9 p.Research output: Contribution to journal › Article › Research › peer-review
10 Citations (Scopus) -
PHACEing a challenging diagnosis: Should we expand the phenotype?
Goergen, S. K., Wong, L. F. & Fahey, M. C., Feb 2025, In: Journal of Medical Imaging and Radiation Oncology. 69, 1, p. 85-87 3 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Pregnancy in women with mitochondrial disease—A literature review and suggested guidance for preconception and pregnancy care
Hui, L., Hayman, P., Buckland, A., Fahey, M. C., Mackey, D. A., Mallett, A. J., Schweitzer, D. R., Stuart, C. P., Yau, W. Y. & Christodoulou, J., Feb 2025, In: Australian and New Zealand Journal of Obstetrics and Gynaecology. 65, 1, p. 30-36 7 p.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access2 Citations (Scopus)